Treebough Therapies

Treebough Therapies is a clinical-stage biotechnology company focused on developing novel, non-cytotoxic differentiation treatments for hematologic malignancies. The company's lead approach involves an oral combination of tetrahydrouridine (THU) and decitabine designed to inhibit DNA-methyltransferase 1 (DNMT1) and induce terminal differentiation in malignant cells, bypassing the toxic side effects of traditional high-dose chemotherapy. Treebough is currently advancing this platform through a Phase 1 clinical trial for relapsed or refractory myelodysplastic syndromes (MDS) in collaboration with the Montefiore Einstein Medical Center. The company’s strategy aims to provide accessible and well-tolerated oral therapeutic options for elderly or frail patients who are often underserved by current standard-of-care hypomethylating agents.